Stroke · 2003 · 118 citations · 9 references
MedicineCommunity HealthCerebrovascular SurgeryDrug Utilization ReviewStroke RehabilitationAcute Ischemic StrokeAcute Stroke CareAcute Stroke ManagementCerebrovascular DiseaseStrokeThrombolytic TherapyAcute Ischemic Stroke InterventionAcute Ischemic Stroke ManagementCerebrovascular Occlusive DiseaseIntravenous Tissue Plasminogen ActivatorPatient Outcomes MeasurementPlasminogen ActivatorsPrimary CentersThrombolysis In Ischemic Stroke
BACKGROUND AND PURPOSE: To increase the proportion of ischemic stroke patients treated with thrombolytic therapy, the establishment of primary stroke centers in community hospitals has been advocated. We evaluated the use of thrombolytic therapy before and after institution of a primary stroke center in a community hospital. METHODS: The availability of an on-call stroke emergency response team was the only significant additional resource required for this hospital. All eligible patients were treated with intravenous tissue plasminogen activator (tPA). The number of patients with cerebrovascular disease, number and proportion of patients treated with tPA, times to treatment, and patient outcomes were recorded during the first 2 years of the stroke center. RESULTS: During the 12 months before institution of the stroke center, 3 ischemic stroke patients (1.5%) were treated with tPA. During the 2-year period of around-the-clock coverage, 44 of 420 ischemic stroke patients (10.5%) were treated with intravenous tPA, a significant increase in tPA use (P<0.0001). CONCLUSIONS: Establishment of a primary stroke center at a community hospital resulted in a substantial increase in the proportion of patients receiving thrombolytic therapy for ischemic stroke. If this experience is generalized, the beneficial impact of primary stroke centers on stroke outcomes and costs to the healthcare system may be substantial.
9
Intravenous Tissue-Type Plasminogen Activator for Treatment of Acute Stroke
Gregory W. Albers, Vernice Bates, Wayne M. Clark et al. · JAMA · 2000 · 707 citations
Medicine, Neurology, Pharmacotherapy +17
Use of Tissue-Type Plasminogen Activator for Acute Ischemic Stroke
Irene Katzan, Anthony J. Furlan, Lynne E. Lloyd et al. · JAMA · 2000 · 659 citations